AstraZeneca

Open: 68.99 Close: 68.79 Change: -0.2

Are you still looking for information about AstraZeneca Company Inc? An AI summarized it for you.

How much time have you spent trying to decide whether investing in AstraZeneca? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: vaccine, AstraZeneca, …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

Oxford–AstraZeneca COVID-19 vaccine is used to provide protection against infection by the SARS-CoV-2 virus. Vaccine developed by Oxford University and British-Swedish company AstraZeneca. South Korea granted approval of the Astra Zeneca vaccine on 10 February 2021.

Today's News

Oxford–AstraZeneca COVID-19 vaccine is used to provide protection against infection by the SARS-CoV-2 virus. Vaccine developed by Oxford University and British-Swedish company AstraZeneca. AstraZeneca revised its efficacy claim to be 76% after further review of the data. South Korea granted approval of the Astra Zeneca vaccine on 10 February 2021, thus becoming the first vaccine to be approved for use in that country. Several Canadian provinces backtrack on NACI recommendation and extend eligibility for AstraZeneca vaccine to residents as young as 40 years old, including Alberta, British Columbia, Ontario, and Saskatchewan. Multiple provinces announced that they would suspend use of the vaccine once again. AstraZeneca and Oxford University collaboration was seen as having the potential as being a low-cost vaccine with no onerous storage requirements. Study of 216 participants found a heterologous prime-boost vaccination course consisting of one dose of the Oxford–AstraZeneca vaccine followed by one dose of the Moderna vaccine. EMA recommends COVID-19 Vaccine AstraZeneca for authorisation in the EU. Side effects for both vaccines can occur at a rate of more than one in 10 doses. AstraZeneca COVID-19 vaccine approved for emergency use in Pakistan, Taiwan and South Korea. South Africa halts Astra Zeneca vaccinations after data shows little protection against mutation. AstraZeneca to supply Japan with 120m COVID-19 vaccine doses. AstraZeneca set to start making 400 million COVID vaccine for Latam early in 2021 AstraZeneca PLC ADR underperforms Thursday when compared to competitors. Prostate Cancer, Generalized Myasthenia Gravis Treatments get Approval in Japan. AstraZecas Alexion to Buy Gene Therapies Portfolio for Up to $1 Bln from Pfizer. Astrazeneca latest drugmaker to challenge medicare price negotiation. CMS plan to start negotiating prices for some of the most expensive drugs. AstraZeneca has filed a lawsuit against the Inflation Reduction Act. The UK-based company says the law prevents drugmakers from developing treatments for rare disease and cancer patients. The Orphan Drug Act incentivizes drugmakers to develop treatments for diseases affecting fewer than 200,000 people. AstraZeneca is the latest in a growing list of pharmaceutical companies, trade organizations, and advocacy groups to challenge the IRAs Medicare price negotiation provisions. The drugmaker argues protecting access to drugs like Lynparza, among other expensive orphan treatments, will have minimal impact on the overall cost to the US. AstraZeneca files legal challenge to protect access to medicines for cancer and rare diseases. Astrazeneca Files Legal Challenge To Protect Access To Medicines For Cancer And Rare Diseases. Company formed in 1999 in Cambridgeshire, the UK.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

Are looking for the most relevant information about AstraZeneca? Investor spend a lot of time searching for information to make investment decisions in AstraZeneca. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: vaccine, AstraZeneca, COVID19, use, develop, company, South, and the most common words in the summary are: astrazeneca, vaccine, covid19, drug, case, best, market, . One of the sentences in the summary was: Vaccine developed by Oxford University and British-Swedish company AstraZeneca. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #vaccine #covid19 #drug #case #best #market.